Susquehanna International Group
ALXO icon

Susquehanna International Group’s ALX Oncology ALXO Stock Holding History

Susquehanna International Group’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.3K Sell
14,100
-1,600
-10% -$3.05K ﹤0.01% 12781
2025
Q4 		$17.7K Sell
15,700
-58,500
-79% -$88.6K ﹤0.01% 11982
2025
Q3 		$136K Buy
+74,200
New +$64.3K ﹤0.01% 11358
2025
Q2 		– Sell
-10,100
Closed -$6.26K – 12579
2025
Q1 		$6.26K Sell
10,100
-5,300
-34% -$6.36K ﹤0.01% 12247
2024
Q4 		$25.7K Sell
15,400
-36,700
-70% -$56.4K ﹤0.01% 11870
2024
Q3 		$94.8K Sell
52,100
-110,300
-68% -$410K ﹤0.01% 11083
2024
Q2 		$979K Buy
162,400
+69,800
+75% +$858K ﹤0.01% 6646
2024
Q1 		$1.03M Sell
92,600
-89,300
-49% -$1.25M ﹤0.01% 6830
2023
Q4 		$2.71M Buy
181,900
+160,400
+746% +$1.52M ﹤0.01% 4750
2023
Q3 		$103K Buy
21,500
+600
+3% +$3.26K ﹤0.01% 10890
2023
Q2 		$157K Buy
20,900
+10,500
+101% +$68.7K ﹤0.01% 10533
2023
Q1 		$47K Sell
10,400
-6,400
-38% -$48.5K ﹤0.01% 11718
2022
Q4 		$189K Sell
16,800
-14,600
-46% -$164K ﹤0.01% 10216
2022
Q3 		$300K Sell
31,400
-13,100
-29% -$153K ﹤0.01% 9784
2022
Q2 		$360K Buy
44,500
+31,700
+248% +$345K ﹤0.01% 9060
2022
Q1 		$216K Buy
+12,800
New +$219K ﹤0.01% 11046
2021
Q4 		– Sell
-44,300
Closed -$3.27M – 13044
2021
Q3 		$3.27M Buy
44,300
+24,100
+119% +$1.61M ﹤0.01% 4776
2021
Q2 		$1.1M Buy
20,200
+1,900
+10% +$114K ﹤0.01% 7492
2021
Q1 		$1.35M Buy
18,300
+12,000
+190% +$944K ﹤0.01% 6940
2020
Q4 		$543K Buy
+6,300
New +$379K ﹤0.01% 8092

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Susquehanna International Group's ALXO Position: Q1 2026 in Review

Susquehanna International Group increased its ALX Oncology (ALXO) stake by 780% in Q1 2026, buying an estimated $2.24M and bringing the position to 1,328,907 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #5525.

Susquehanna International Group first reported a position in ALXO in Q4 2020 and has held it in 20 quarters since. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Susquehanna International Group held 1,328,907 shares of ALX Oncology worth $2.66M as of Q1 2026.
  • Susquehanna International Group bought 1,177,880 ALX Oncology shares in Q1 2026, an estimated $2.24M.
  • ALX Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5525 holding.
  • Susquehanna International Group first reported a position in ALX Oncology in Q4 2020 and has held it in 20 quarters since.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.